JHLT Open (Feb 2024)

Mechanical circulatory support in pediatric myocarditis: Support strategies and outcomes in a nationally representative cohort

  • Alicia M. Kamsheh,
  • Jonathan B. Edelson,
  • Jennifer Faerber,
  • Antara Mondal,
  • William Quarshie,
  • Jonathan J. Edwards,
  • Kimberly Y. Lin,
  • Matthew J. O’Connor,
  • Carol Wittlieb-Weber,
  • Katsuhide Maeda,
  • Michael P. Goldsmith,
  • Joseph W. Rossano

Journal volume & issue
Vol. 3
p. 100026

Abstract

Read online

Background: Myocarditis is a common cause of pediatric heart failure which may require mechanical circulatory support (MCS). The purpose of this study is to describe MCS strategies used in a nationwide cohort of pediatric patients with myocarditis, identify trends over time, and compare outcomes between MCS strategies. Methods: This study utilized the Kids’ Inpatient Database (KID), a national sample of administrative discharge data. KID admissions from 2003 to 2016 were queried using ICD-9/10 codes to identify those with a diagnosis of myocarditis. MCS outcomes were compared using logistic regression. Results: Of 5,661 admissions for myocarditis, MCS was used in 424 (7.5%), comprised of extracorporeal membrane oxygenation (ECMO) in 312 (73.6%), including 32 (10.2%) instances of extracorporeal cardiopulmonary resuscitation (ECPR), temporary ventricular assist devices (VAD) in 28 (6.6%), durable VAD in 42 (9.9%) and combination MCS in 42 (9.9%). MCS use increased over time (p = 0.031), but MCS strategies did not significantly change. Mortality was high in the MCS group (28.3%). There was no difference in odds of death in the VAD only or combination MCS group compared to the non-ECPR ECMO group (p = 0.07 and p = 0.65, respectively). Conclusions: MCS is used in 1 in 13 pediatric myocarditis cases, and MCS use is increasing over time with ECMO remaining the most frequently used modality. Mortality remains high in patients that receive MCS but does not differ between those receiving VAD or combination MCS as compared to non-ECPR ECMO on unadjusted analysis. Further prospective analysis is required to evaluate the relative effectiveness of MCS modalities in this disease.

Keywords